A small-molecule antagonist of the β-catenin/TCF4 interaction blocks the self-renewal of cancer stem cells and suppresses tumorigenesis

Cancer Research

Volumn 76, Issue 4, 2016, Pages 891-901

  Fang, Liang ^a   Zhu, Qionghua ^a   Neuenschwander, Martin ^b   Specker, Edgar ^b   Wulf Goldenberg, Annika ^c   Weis, William I ^d   Von Kries, Jens P ^b   Birchmeier, Walter ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

^c Exp Pharmacol Oncol Berlin B   (Germany)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 THIOUREIDOBENZENESULFONAMIDE DERIVATIVE; BENZENESULFONAMIDE DERIVATIVE; BETA CATENIN; CADHERIN; LF 3; TCF4 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCHEMICAL ANALYSIS; CANCER CELL; CANCER GROWTH; CANCER STEM CELL; CARCINOGENESIS; CELL ADHESION; CELL CYCLE; CELL DIFFERENTIATION; CELL MOTILITY; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; GENE TARGETING; HEAD AND NECK CANCER; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT; WNT SIGNALING PATHWAY; ANIMAL; CELL TRANSFORMATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; BETA CATENIN; CARCINOGENESIS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; WNT SIGNALING PATHWAY;

EID: 84960438593     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1519     Document Type: Article

References (50)

1. Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci 2015;36:422-39.
2. Groth C, Fortini ME. Therapeutic approaches to modulating Notch signaling: current challenges and future prospects. Semin Cell Dev Biol 2012; 23:465-72.
3. Basset-Seguin N, Sharpe HJ, de Sauvage FJ. Efficacy of Hedgehog pathway inhibitors in basal cell carcinoma. Mol Cancer Ther 2015;14:633-41.
4. Polakis P. Drugging Wnt signalling in cancer. Embo J 2012;31:2737-46.
5. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781-810.
6. Grigoryan T, Wend P, Klaus A, Birchmeier W. Deciphering the function of canonical Wnt signals in development and disease: conditional loss-and gain-of-function mutations of beta-catenin in mice. Genes Dev 2008;22: 2308-41.
7. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469-80.
8. de Lau W, Barker N, Clevers H. WNT signaling in the normal intestine and colorectal cancer. Front Biosci 2007;12:471-91.
9. Tennis M, Van Scoyk M, Winn RA. Role of the wnt signaling pathway and lung cancer. J Thorac Oncol 2007;2:889-92.
10. Robinson DR, Zylstra CR, Williams BO. Wnt signaling and prostate cancer. Curr Drug Targets 2008;9:571-80.
11. Takigawa Y, Brown AM. Wnt signaling in liver cancer. Curr Drug Targets. 2008;9:1013-24.
12. Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, Berger AJ, et al. Activated Wnt/beta-catenin signaling inmelanoma is associated with decreased proliferation in patient tumors and a murinemelanoma model. Proc Natl Acad Sci U S A 2009;106:1193-8.
13. Stein U, Arlt F, Walther W, Smith J, Waldman T, Harris ED, et al. The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology 2006;131: 1486-500.
14. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 2009;138:51-62.
15. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009;457:608-11.
16. Wend P, Fang L, Zhu Q, Schipper JH, Loddenkemper C, Kosel F, et al. Wnt/beta-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours. Embo J 2013;32:1977-89.
17. Holland JD, Gyorffy B, Vogel R, Eckert K, Valenti G, Fang L, et al. Combined Wnt/beta-catenin, Met, and CXCL12/CXCR4 signals characterize basal breast cancer and predict disease outcome. Cell Rep 2013; 5:1214-27.
18. Malanchi I, PeinadoH, Kassen D, Hussenet T,Metzger D,Chambon P, et al. Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 2008;452:650-3.
19. Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, Borovski T, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010;12:468-76.
20. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell. 2004;5:91-102.
21. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, et al. Small moleculemediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009;5:100-7.
22. Shan J, Shi DL, Wang J, Zheng J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry 2005;44:15495-503.
23. Grandy D, Shan J, Zhang X, Rao S, Akunuru S, Li H, et al. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J Biol Chem 2009;284:16256-63.
24. Waaler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR, et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res 2012;72:2822-32.
25. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009;461:614-20.
26. Eguchi M, Nguyen C, Lee SC, Kahn M. ICG-001, a novel small molecule regulator of TCF/beta-catenin transcription. Med Chem (Shariqah (United Arab Emirates)) 2005;1:467-72.
27. Gonsalves FC, Klein K, Carson BB, Katz S, Ekas LA, Evans S, et al. An RNAibased chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc Natl Acad Sci U S A. 2011; 108:5954-63.
28. de la RocheM, Rutherford TJ, Gupta D, Veprintsev DB, Saxty B, Freund SM, et al. An intrinsically labile alpha-helix abutting the BCL9-binding site of beta-catenin is required for its inhibition by carnosic acid. Nat Commun. 2012;3:680.
29. Jang GB, Hong IS, Kim RJ, Lee SY, Park SJ, Lee ES, et al. Wnt/beta-Catenin small-molecule inhibitor CWP232228 preferentially inhibits the growth of breast cancer stem-like cells. Cancer Res 2015;75:1691-702.
30. Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov 2014;13:513-32.
31. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007;450:1001-9.
32. von Kries JP, Winbeck G, Asbrand C, Schwarz-Romond T, Sochnikova N, Dell'Oro A, et al. Hot spots in beta-catenin for interactions with LEF-1, conductin and APC. Nat Struct Biol 2000;7:800-7.
33. Choi HJ, Huber AH, Weis WI. Thermodynamics of beta-catenin-ligand interactions: the roles of theN-and C-terminal tails in modulating binding affinity. J Biol Chem 2006;281:1027-38.
34. Lisurek M, Rupp B, Wichard J, Neuenschwander M, von Kries JP, Frank R, et al. Design of chemical libraries with potentially bioactive molecules applying a maximum common substructure concept. Mol Divers 2010; 14:401-8.
35. Eglen RM, Reisine T, Roby P, Rouleau N, Illy C, Bosse R, et al. The use of AlphaScreen technology in HTS: current status. Curr Chem Genomics 2008;1:2-10.
36. Omer CA, Miller PJ, Diehl RE, Kral AM. Identification of Tcf4 residues involved in high-affinity beta-catenin binding. Biochem Biophys Res Commun 1999;256:584-90.
37. Fasolini M, Wu XQ, Flocco M, Trosset JY, Oppermann U, Knapp S. Hot spots in Tcf4 for the interaction with beta-catenin. J Biol Chem 2003; 278:21092-8.
38. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26.
39. Sineva GS, Pospelov VA. Inhibition of GSK3beta enhances both adhesive and signalling activities of beta-catenin in mouse embryonic stem cells. Biol Cell 2010;102:549-60.
40. Wong MH, Huelsken J, Birchmeier W, Gordon JI. Selection ofmultipotent stem cells during morphogenesis of small intestinal crypts of Lieberkuhn is perturbed by stimulation of Lef-1/beta-catenin signaling. J Biol Chem 2002;277:15843-50.
41. Hulsken J, Birchmeier W, Behrens J. E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. J Cell Biol 1994;127: 2061-9.
42. Pai LM, Kirkpatrick C, Blanton J, Oda H, Takeichi M, Peifer M. Drosophila alpha-catenin and E-cadherin bind to distinct regions of Drosophila Armadillo. J Biol Chem 1996;271:32411-20.
43. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1994;1198:11-26.
44. Lukacs RU, Memarzadeh S, Wu H, Witte ON. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell 2010;7:682-93.
45. Wend P, Holland JD, Ziebold U, Birchmeier W. Wnt signaling in stem and cancer stem cells. Semin Cell Dev Biol 2010;21:855-63.
46. Holland JD, Klaus A, Garratt AN, Birchmeier W. Wnt signaling in stem and cancer stem cells. Curr Opin Cell Biol 2013;25:254-64.
47. Vo N, Goodman RH. CREB-binding protein and p300 in transcriptional regulation. J Biol Chem 2001;276:13505-8.
48. Jin L, Wang W, Fang G. Targeting protein-protein interaction by small molecules. Annu Rev Pharmacol Toxicol 2014;54:435-56.
49. Trosset JY, Dalvit C, Knapp S, Fasolini M, Veronesi M, Mantegani S, et al. Inhibition of protein-protein interactions: the discovery of druglike betacatenin inhibitors by combining virtual and biophysical screening. Proteins 2006;64:60-7.
50. Li F, Tiede B, Massague J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 2007;17:3-14.